Susquehanna International Group, LLP Apellis Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 171,792 shares of APLS stock, worth $5.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171,792

Previous 478,963 64.13%

Holding current value

$5.69 Million

Previous $18.4 Million 73.04%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $8.86 Million - $12.6 Million	-307,171 Reduced 64.13%	171,792 $4.95 Million
Q2 2024 Aug 15, 2024	BUY	$38.07 - $59.71 $8.94 Million - $14 Million	234,702 Added 96.09%	478,963 $18.4 Million
Q1 2024 May 07, 2024	SELL	$55.39 - $72.47 $7.68 Million - $10 Million	-138,571 Reduced 36.2%	244,261 $14.4 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $373,145 - $651,246	10,047 Added 2.7%	382,832 $22.9 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $1.35 Million - $5.07 Million	56,875 Added 18.0%	372,785 $14.2 Million
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $18 Million - $21.8 Million	234,114 Added 286.22%	315,910 $28.8 Million
Q1 2023 May 16, 2023	BUY	$46.59 - $66.96 $2.33 Million - $3.35 Million	50,064 Added 157.77%	81,796 $5.4 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $1.13 Million - $1.59 Million	-26,128 Reduced 45.16%	31,732 $1.64 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $182,620 - $284,212	4,080 Added 7.59%	57,860 $3.95 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $766,454 - $1.29 Million	-21,855 Reduced 28.9%	53,780 $2.43 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $244,177 - $372,670	6,886 Added 10.02%	75,635 $3.84 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.25 Million - $2 Million	-40,661 Reduced 37.16%	68,749 $3.25 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $2.53 Million - $5.63 Million	80,641 Added 280.31%	109,410 $3.61 Million
Q2 2021 Aug 11, 2021	BUY	$40.9 - $64.9 $116,401 - $184,705	2,846 Added 10.98%	28,769 $1.82 Million
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $497,066 - $699,182	12,183 Added 88.67%	25,923 $1.11 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $896,081 - $1.66 Million	-29,103 Reduced 67.93%	13,740 $786,000
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $1.19 Million - $1.54 Million	-45,818 Reduced 51.68%	42,843 $1.29 Million
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $920,898 - $1.43 Million	-37,133 Reduced 29.52%	88,661 $2.9 Million
Q1 2020 May 15, 2020	SELL	$17.91 - $44.33 $99,185 - $245,499	-5,538 Reduced 4.22%	125,794 $3.37 Million
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $1.5 Million - $2.1 Million	68,034 Added 107.48%	131,332 $4.02 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $682,276 - $911,401	28,322 Added 80.98%	63,298 $1.52 Million
Q2 2019 Aug 16, 2019	BUY	$18.0 - $25.34 $629,568 - $886,291	34,976 New	34,976 $886,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Apellis Pharmaceuticals, Inc. Transaction History